The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Evaluating cell lines as tumour models by comparison of genomic profiles
Open accessAbstract
Cancer cell lines are frequently used as in vitro tumour models. Recent molecular profiles of hundreds of cell lines from The Cancer Cell Line Encyclopedia and thousands of tumour samples from the Cancer Genome Atlas now allow a systematic genomic comparison of cell lines and tumours. Here we analyse a panel of 47 ovarian cancer cell lines and identify those that have the highest genetic similarity to ovarian tumours. Our comparison of copy-number changes, mutations and mRNA expression profiles reveals pronounced differences in molecular profiles between commonly used ovarian cancer cell lines and high-grade serous ovarian cancer tumour samples. We identify several rarely used cell lines that more closely resemble cognate tumour profiles than commonly used cell lines, and we propose these lines as the most suitable models of ovarian cancer. Our results indicate that the gap between cell lines and tumours can be bridged by genomically informed choices of cell line models for all tumour types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hierarchical Grouping to Optimize an Objective Function
Ward, J. H. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500845 · Cited by 20,598
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Self-citation
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Self-citationAn organoid platform for ovarian cancer captures intra- and interpatient heterogeneity
Kopper, O., de Witte, C. J., Lõhmussaar, K., Valle-Inclan, J. E., Hami, N., Kester, L., Balgobind, A. V., Korving, J., Proost, N., Begthel, H., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0422-6 · Cited by 834
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00012 · Cited by 754
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040952 · Cited by 680
A survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555
Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip
Zhang, P., Zhou, X., He, M., Shang, Y., Tetlow, A. L., Godwin, A. K., & Zeng, Y. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0356-9 · Cited by 554
Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death
Tesfay, L., Paul, B. T., Konstorum, A., Deng, Z., Cox, A. O., Lee, J., Furdui, C. M., Hegde, P., Torti, F. M., & Torti, S. V. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0369 · Cited by 551
Isolation and characterization of extracellular vesicle subpopulations from tissues
Crescitelli, R., Lässer, C., & Lötvall, J. (2021) · Nature Protocols · doi:10.1038/s41596-020-00466-1 · Cited by 507
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
Iron addiction: a novel therapeutic target in ovarian cancer
Basuli, D., Tesfay, L., Deng, Z., Paul, B., Yamamoto, Y., Ning, G., Xian, W., McKeon, F., Lynch, M., Crum, C. P., et al. (2017) · Oncogene · doi:10.1038/onc.2017.11 · Cited by 465
Cancer Cell Lines for Drug Discovery and Development
Wilding, J. L., & Bodmer, W. F. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2971 · Cited by 432
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer
Wang, W., Kryczek, I., Dostál, L., Lin, H., Tan, L., Zhao, L., Lu, F., Wei, S., Maj, T., Peng, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.009 · Cited by 422
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
“Comparison of our results with the two earlier studies [31,57] shows similar prediction for HGS and some discrepancies for the non-serous cell lines.”
BackgroundResultIGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner
Müller, S., Glaß, M., Singh, A. K., Haase, J., Bley, N., Fuchs, T., Lederer, M., Dahl, A., Huang, H., Chen, J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1012 · Cited by 379
Liao, L., Liu, J., Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Hammond, P. T., & Johnson, J. A. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502011g · Cited by 362
Challagundla, K. B., Wise, P. M., Neviani, P., Chava, H., Murtadha, M., Xu, T., Kennedy, R., Ivan, C., Zhang, X., Vannini, I., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv135 · Cited by 359
Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers
Skotland, T., Ekroos, K., Kauhanen, D., Simolin, H., Seierstad, T., Berge, V., Sandvig, K., & Llorente, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.011 · Cited by 341
Correlation of an epigenetic mitotic clock with cancer risk
Yang, Z., Wong, A., Kuh, D., Paul, D. S., Rakyan, V. K., Leslie, R. D., Zheng, S. C., Widschwendter, M., Beck, S., & Teschendorff, A. E. (2016) · Genome Biology · doi:10.1186/s13059-016-1064-3 · Cited by 325
Translational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293
Kondrashova, O., Topp, M., Nesic, K., Lieschke, E., Ho, G.-Y., Harrell, M. I., Zapparoli, G. V., Hadley, A., Holian, R., Boehm, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05564-z · Cited by 296
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis
Curtis, M., Kenny, H. A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.007 · Cited by 290
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Goodspeed, A., Heiser, L. M., Gray, J. W., & Costello, J. C. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 276
Choosing the right cell line for renal cell cancer research
Brodaczewska, K. K., Szczylik, C., Fiedorowicz, M., Porta, C., & Czarnecka, A. M. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0565-8 · Cited by 267
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Aref, A. R., Campisi, M., Ivanova, E., Portell, A., Larios, D., Piel, B. P., Mathur, N., Zhou, C., Coakley, R. V., Bartels, A., et al. (2018) · Lab on a Chip · doi:10.1039/c8lc00322j · Cited by 265
Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194
Noninvasive ovarian cancer biomarker detection via an optical nanosensor implant
Williams, R. M., Lee, C., Galassi, T. V., Harvey, J. D., Leicher, R., Sirenko, M., Dorso, M. A., Shah, J., Olvera, N., Dao, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aaq1090 · Cited by 183
“These cell lines are thought to represent HGSC with the exception of SK-OV-3, which is likely not of HGSC origin (40).”
BackgroundSelf-citationCo-evolution of Matrisome and Adaptive Adhesion Dynamics Drives Ovarian Cancer Chemoresistance
Pietilä, E. A., Gonzalez-Molina, J., Moyano-Galceran, L., Jamalzadeh, S., Zhang, K., Lehtinen, L., Turunen, S. P., Martins, T. A., Gultekin, O., Lamminen, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24009-8 · Cited by 175
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
Diaz Osterman, C. J., Ozmadenci, D., Kleinschmidt, E. G., Taylor, K. N., Barrie, A. M., Jiang, S., Bean, L. M., Sulzmaier, F. J., Jean, C., Tancioni, I., et al. (2019) · eLife · doi:10.7554/elife.47327 · Cited by 145
Liu, J. F., Palakurthi, S., Zeng, Q., Zhou, S., Ivanova, E., Huang, W., Zervantonakis, I. K., Selfors, L. M., Shen, Y., Pritchard, C. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1237 · Cited by 127
Harnessing the predictive power of preclinical models for oncology drug development
Honkala, A., Malhotra, S. V., Kummar, S., & Junttila, M. R. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00301-6 · Cited by 121
Characterization of Ovarian Cancer Cell Lines as In Vivo Models for Preclinical Studies
Hernandez, L., Kim, M. K., Lyle, L. T., Bunch, K. P., House, C. D., Ning, F., Noonan, A. M., & Annunziata, C. M. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.05.028 · Cited by 121
Hallas-Potts, A., Dawson, J. C., & Herrington, C. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41941-4 · Cited by 110
High variability of genomic instability and gene expression profiling in different HeLa clones
Frattini, A., Fabbri, M., Valli, R., De Paoli, E., Montalbano, G., Gribaldo, L., Pasquali, F., & Maserati, E. (2015) · Scientific Reports · doi:10.1038/srep15377 · Cited by 109
Bowen, A., & Casadevall, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504955112 · Cited by 104
Patient-derived Xenograft Models to Improve Targeted Therapy in Epithelial Ovarian Cancer Treatment
Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00295 · Cited by 100
Wang, D., Wang, M., Jiang, N., Zhang, Y., Bian, X., Wang, X., Roberts, T. M., Zhao, J. J., Liu, P., & Cheng, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7549 · Cited by 88
Leung, K. K., Wilson, G. M., Kirkemo, L. L., Riley, N. M., Coon, J. J., & Wells, J. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917947117 · Cited by 83
Yee, C., Dickson, K.-A., Muntasir, M. N., Ma, Y., & Marsh, D. J. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.836984 · Cited by 66
Fransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
Computational models for predicting drug responses in cancer research
Azuaje, F. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw065 · Cited by 59
An omentum-inspired 3d peg hydrogel for identifying ecm-drivers of drug resistant ovarian cancer
Brooks, E. A., Gencoglu, M. F., Corbett, D. C., Stevens, K. R., & Peyton, S. R. (2019) · APL Bioengineering · doi:10.1063/1.5091713 · Cited by 51
Kaipio, K., Chen, P., Roering, P., Huhtinen, K., Mikkonen, P., Östling, P., Lehtinen, L., Mansuri, N., Korpela, T., Potdar, S., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5356 · Cited by 54
Ibrahim, L. I., Hajal, C., Offeddu, G. S., Gillrie, M. R., & Kamm, R. D. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121728 · Cited by 53
The Endometriotic Tumor Microenvironment in Ovarian Cancer
Wendel, J. R. H., Wang, X., & Hawkins, S. M. (2018) · Cancers · doi:10.3390/cancers10080261 · Cited by 51
Stover, E. H., Baco, M. B., Cohen, O., Li, Y. Y., Christie, E. L., Bagul, M., Goodale, A., Lee, Y., Pantel, S., Rees, M. G., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1243 · Cited by 49
“org Mol Cancer Res; 17(11) November 2019 2287”
BackgroundMethodInfluentialSingle cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer
Velletri, T., Villa, C. E., Cilli, D., Barzaghi, B., Lo Riso, P., Lupia, M., Luongo, R., López-Tobón, A., De Simone, M., Bonnal, R. J. P., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-021-00878-w · Cited by 48
Mikuła-Pietrasik, J., Sosińska, P., Naumowicz, E., Maksin, K., Piotrowska, H., Woźniak, A., Szpurek, D., & Książek, K. (2016) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9753-y · Cited by 46
Ciucci, A., Zannoni, G. F., Buttarelli, M., Lisi, L., Travaglia, D., Martinelli, E., Scambia, G., & Gallo, D. (2016) · Oncotarget · doi:10.18632/oncotarget.6943 · Cited by 46
WNT7A Regulation by miR-15b in Ovarian Cancer
MacLean, J. A., King, M. L., Okuda, H., & Hayashi, K. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156109 · Cited by 43
Henry, C., Hacker, N., & Ford, C. (2017) · Oncotarget · doi:10.18632/oncotarget.22559 · Cited by 37
Buttarelli, M., Ciucci, A., Palluzzi, F., Raspaglio, G., Marchetti, C., Perrone, E., Minucci, A., Giacò, L., Fagotti, A., Scambia, G., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02265-w · Cited by 32
“We also tested, for comparison, the cytotoxicity of cisplatin and paclitaxel on a panel of established cell lines, selected among those considered as really representative of HGSOC [15, 37].”
Colombo, P.-E., du Manoir, S., Orsetti, B., Bras-Gonçalves, R., Lambros, M. B., MacKay, A., Nguyen, T.-T., Boissière, F., Pourquier, D., Bibeau, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5069 · Cited by 34
Mesothelial Cells Facilitate Cancer Stem like properties in spheroids of ovarian cancer cells
Shishido, A., Mori, S., Yokoyama, Y., Hamada, Y., Minami, K., Qian, Y., Wang, J., Hirose, H., Wu, X., Kawaguchi, N., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6605 · Cited by 34
Heredia-Soto, V., Redondo, A., Berjón, A., Miguel-Martín, M., Díaz, E., Crespo, R., Hernández, A., Yébenes, L., Gallego, A., Feliu, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25098 · Cited by 33
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31
Detappe, A., Mathieu, C., Jin, C., Agius, M. P., Diringer, M.-C., Tran, V.-L., Pivot, X., Lux, F., Tillement, O., Kufe, D., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.069 · Cited by 27
Gambaro, K., Quinn, M. C., Cáceres-Gorriti, K. Y., Shapiro, R. S., Provencher, D., Rahimi, K., Mes-Masson, A.-M., & Tonin, P. N. (2015) · BMC Cancer · doi:10.1186/s12885-015-1138-8 · Cited by 21
Boussommier-Calleja, A. (2020) · Bioengineering Innovative Solutions for Cancer · doi:10.1016/b978-0-12-813886-1.00013-9 · Cited by 10
Smith, H. L., Willmore, E., Mukhopadhyay, A., Drew, Y., & Curtin, N. J. (2022) · Cancers · doi:10.3390/cancers14225559 · Cited by 9
Metadata
- Authors
- Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N.
- Venue
- Nature Communications
- Published
- 2013-07-09
- Volume
- 4
- Issue
- 1
- Pages
- 2126-2126
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W1997338647
- Cited by
- 1,418
- References
- 53
- FWCI
- 106.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.